WHX 2026: Arcera’s Mansoor Menai on antibiotic innovation, healthcare access
Mansoor Meenai, GM for META at Arcera, outlines how the company is positioning itself across hospital-based therapies and consumer health
10 February, 2026
TT
16
As healthcare systems across the GCC confront rising demand, supply-chain pressure, and the growing threat of antimicrobial resistance, life sciences companies are being pushed to deliver both innovation and execution.
Here, Mansoor Meenai, GM for META at Arcera, outlines how the company is positioning itself across hospital-based therapies and consumer health, with a focus on responsible antibiotic use, regional manufacturing, and translating science into real-world access.
What are you displaying at WHX in Dubai 2026?
At World Health Expo Dubai 2026, we are showcasing Arcera’s broader role in strengthening healthcare systems across the region, from addressing critical unmet medical needs to expanding access to trusted self-care solutions.
On the speciality side, we are highlighting a breakthrough intravenous antibiotic approach that represents a meaningful step forward in the fight against antimicrobial resistance. This innovation offers a carbapenem-sparing option, enabling clinicians to treat serious resistant infections effectively while reducing reliance on last-line antibiotics that must be preserved for the most critical cases. In doing so, it directly supports national antimicrobial stewardship programs and long-term healthcare resilience.
We have moved with focus and discipline to ensure strong launch execution across the GCC, recognising that addressing antibiotic resistance is a critical priority for sustainable healthcare systems.
Beyond hospital-based innovation, WHX also reflects our commitment to enhancing everyday health. As part of our mission to improve patient and consumer access to high-quality care, we are advancing a strong consumer healthcare portfolio that empowers individuals to take charge of their health through trusted, science-backed self-care solutions.
Across everything we do, quality, reliability, and consumer-first design remain central. WHX 2026 is an opportunity to demonstrate how Arcera is redefining access to care, across acute treatment and self-care alike, by delivering trusted innovation that strengthens health systems and improves lives.
Read: AI, prevention and policy alignment take focus at WHX in Dubai
What are some of the anticipated trends for 2026?
In 2026, healthcare systems across the region and globally are facing a combination of rising demand and growing complexity, from regulation and supply chains to evolving patient needs.
This year, we expect continued demand for high-quality medicines across both emerging and developed markets, alongside increasing complexity in regulation, supply chains, and patient needs.
One trend that is especially clear in the GCC is the focus on strengthening local and regional manufacturing. Governments are prioritising supply-chain resilience for essential medicines, reducing reliance on long global routes, and ensuring continuity of care, particularly for chronic and critical conditions.
Another important area of focus is antimicrobial resistance. The World Health Organization continues to recognise antimicrobial resistance (AMR)as a significant global health challenge. In response, healthcare systems are increasingly seeking treatment approaches that support responsible antibiotic use while maintaining effective patient outcomes.
At the same time, healthcare is becoming more data-driven and digitally enabled, with advanced analytics and AI influencing how medicines are developed, manufactured, and delivered.
Taken together, these trends point to a broader shift toward healthcare systems that are more resilient, adaptive, and future-ready, and to the growing importance of long-term partnerships between industry, governments, and healthcare stakeholders.
Any key innovations and technologies to look out for in 2026?
Innovation in 2026 will be defined not just by scientific advances, but by how effectively those advances are translated into real-world patient access, particularly in fast-evolving regions such as the GCC.
One of the most critical areas of innovation remains AMR. As resistance to standard antibiotics continues to rise, healthcare systems across the region are seeking treatment approaches that preserve last-line therapies while maintaining clinical effectiveness. Beyond infectious diseases, neuroscience is emerging as another important innovation frontier. As populations age and the prevalence of neurological conditions increases, the need for new, effective therapies will continue to grow.
From a technology perspective, the integration of digital tools and advanced analytics across the healthcare value chain is accelerating, improving efficiency, reliability, and decision-making from development
and manufacturing through to engagement with healthcare professionals.
At the same time, innovation is also taking place in how people manage their everyday health. High-quality, science-led consumer health solutions are playing an increasingly important role in empowering individuals, supporting self-care, and helping healthcare systems focus resources where they are needed most.
In this context, Arcera’s role is to translate innovation into access, working across the GCC and selected global markets as a strategic partner aligned with long-term public-health priorities.
How do you see growth in the industry?
The life sciences sector is undergoing strong and sustained growth across the Middle East and the GCC. We are seeing accelerating healthcare investment, expanding infrastructure and a clear government focus on access, quality, and long-term sustainability.
At the same time, regulatory frameworks are becoming more sophisticated, with rising expectations around manufacturing standards, pharmacovigilance, and compliance.
Across the region, this creates not only significant growth opportunities but also the conditions needed to build healthcare systems that are more resilient, reliable, and capable of meeting future patient needs.
What are your plans and the way forward?
Arcera was created to build a future-ready global life sciences enterprise — relevant to healthcare systems around the world.
As we look ahead, our priorities are clear. We will continue to scale our enterprise while deepening innovation, scientifically, digitally, and operationally.
We are investing in advanced therapies, resilient manufacturing, and next-generation capabilities that enable us to deliver high-quality medicines reliably, at scale, and across diverse markets.
We also strongly support the UAE’s ambition to strengthen local pharmaceutical manufacturing.
Today, over 40 per cent of our UAE portfolio is produced locally, enhancing national health security, reducing supply-chain risk, and enabling faster response to changing patient needs.
This balance between global scale and strong local execution is central to building healthcare systems that are resilient today and adaptable for the future.
Looking ahead, we will continue to expand long-term partnerships across government, academia, and industry.
Above all, we remain focused on the needs of patients and healthcare professionals.
Arcera is being built not just to grow, but to endure, as a trusted partner contributing to sustainable progress in global healthcare.


















